What is Cresilon?
Cresilon operates at the intersection of advanced materials science and clinical medicine. The company specializes in the development, manufacturing, and commercialization of innovative hemostatic devices that utilize a unique, proprietary hydrogel platform. This technology is designed to address critical challenges in wound management and surgical bleeding, offering superior performance compared to traditional methods. By maintaining a focus on high-impact medical applications, Cresilon has established a strong market position, effectively bridging the gap between laboratory-scale innovation and large-scale clinical deployment. Its commitment to research and development ensures that its product pipeline remains at the forefront of the biotechnology industry, catering to the evolving needs of healthcare providers and patients alike.
How much funding has Cresilon raised?
Cresilon has raised a total of $68.8M across 4 funding rounds:
Debt
$350K
Series A
$38.5M
Other Financing Round
$25M
Debt
$5M
Debt (2020): $350K with participation from PPP
Series A (2021): $38.5M, investors not publicly disclosed
Other Financing Round (2022): $25M supported by Paulson Investment Company
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Cresilon
Paulson Investment Company
Paulson Investment Company is a boutique investment banking and broker-dealer firm that focuses on serving small and mid-sized companies through capital markets expertise and long-term financial advisory services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Cresilon?
With the recent influx of capital, Cresilon is well-positioned to accelerate its commercial expansion and deepen its research initiatives. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the rising demand for its hydrogel-based solutions while simultaneously navigating the regulatory pathways required for broader market penetration. As the company matures, the emphasis will remain on optimizing its supply chain and expanding its footprint within the global medical device landscape. Investors and industry analysts will be closely monitoring how this latest financing round facilitates the transition from a specialized biotech developer to a dominant force in the surgical technology market, potentially setting the stage for future strategic partnerships or further capital market engagement.
See full Cresilon company page
